Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
about
Renal effects of dapagliflozin in patients with type 2 diabetesNew Pathogenic Concepts and Therapeutic Approaches to Oxidative Stress in Chronic Kidney DiseaseCurrent Challenges in Diabetic Nephropathy: Early Diagnosis and Ways to Improve OutcomesThe EMPA-REG outcome study: critical appraisal and potential clinical implicationsDifferential pharmacology and clinical utility of empagliflozin in type 2 diabetesSGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetesInsulin sensitivity and complications in type 1 diabetes: New insightsBeat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agentsDiabetic kidney disease: a report from an ADA Consensus ConferenceEarly diabetic nephropathy in type 1 diabetes: new insightsHeart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic ReviewSodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effectsRodent models of diabetic nephropathy: their utility and limitationsSodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A ReviewImprovements in the Management of Diabetic NephropathySGLT2 Inhibitors May Predispose to KetoacidosisProtein- and diabetes-induced glomerular hyperfiltration: role of glucagon, vasopressin, and ureaEffect of Acetazolamide on Obesity-Induced Glomerular Hyperfiltration: A Randomized Controlled TrialRecent advances in CKD and ESRD: A literature update.Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials.Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta-analysis of data from randomized placebo-controlled trialsEffects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis.Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials.The effects of glucose-lowering therapies on diabetic kidney diseaseSodium-glucose Co-transporter 2 Inhibitors Reduce the Abdominal Visceral Fat Area and May Influence the Renal Function in Patients with Type 2 Diabetes.Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitusUpdate on developments with SGLT2 inhibitors in the management of type 2 diabetesDiabetic nephropathy for the primary care provider: new understandings on early detection and treatmentDiabetic nephropathy - complications and treatment.Empagliflozin in the treatment of type 2 diabetes: evidence to dateThe effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.The urinary cytokine/chemokine signature of renal hyperfiltration in adolescents with type 1 diabetes.Dapagliflozin for the treatment of type 2 diabetes: a review of the literature
P2860
Q24564811-432B0F43-B334-4B2B-AF3F-C834F1684E51Q26739475-8E67EC2E-E802-4E4E-AF42-0A3760D2FD9CQ26744419-9492F6E9-6274-4556-AF03-FC22F956538DQ26748742-429BE31F-A9D9-4543-AEB1-8EF33E02B9A6Q26749281-1F28CB4D-328B-4CEF-A4BF-B74181E84FA4Q26750510-C01A7D5C-81F9-4F90-B576-8461C18CBAB4Q26864336-8F417D70-CF1C-42BE-AE8F-BD2B59B2289DQ27000205-37A834A3-7426-49C4-8214-E9FDC408A936Q27010669-A0838306-B8DD-4F62-849F-8C18ABCEC5B0Q27012546-F81D29C0-41E1-461E-8079-66AD2A32E82FQ27021632-D188D28A-DC3D-479C-B411-9E8C8343C563Q27301948-198F29E6-866A-4D7E-ADD6-E3FD9ECA440DQ28072352-E0D7688A-28F1-497F-8B6C-341A030A0160Q28072765-8B83539A-8698-41D6-98C2-49D1C03E62BAQ28073885-09FAE8B0-ED66-401E-8202-699EF1D8D688Q28079134-B7D08C05-A5BA-4189-AA30-73B1A71F00F6Q28080717-075829AE-6E88-4C29-BE44-F48723632C6CQ28081173-C690E7CF-2DD3-4419-95F5-06152C8D3C66Q28085593-7DDF4EC5-57C9-43F1-9D91-4857AC2486A8Q28547970-8A5D8B04-5AC8-47FB-AAA4-6F29557BDE51Q30275339-71C4E47C-4011-46B0-BD92-E76CCD0C9E76Q31025919-CDFE18B5-1BDE-4C5B-955D-E5C51B65D253Q31105792-F560BA6C-F547-457B-B9C0-7E55ED127051Q31112303-83671C63-87E1-4619-9D3C-1466A3A0F71FQ32186373-9E562AA8-BE70-45F2-AEF5-9096D61333FAQ33166813-7300620C-2517-4401-9A8D-5AA3B6D04A57Q33583220-493A0531-E5BD-4F4B-A5EB-AA911C4B772DQ33619161-0071FBBE-E60F-4789-9E84-CC53AB7E2957Q33625568-EA3F41A9-009F-49BB-91AA-126DF7B27BD8Q33696974-3D084635-DA7C-4624-8B42-37E721FDCF2CQ33812170-EED14B9B-57B5-4E66-9BCB-870A2E76310EQ33837017-1E490392-C33A-4C3B-AE0B-93329DDEF840Q33871321-9139B6C4-6036-4B84-AA5A-FEAC10BAF604Q34198692-777D7D8F-36CC-4789-81B7-7BF0922F238EQ34228586-B35E613C-6385-4EED-B692-7D04D7E74A94Q34387952-07B87F03-1C46-4F69-8281-4939D5BBEACFQ34502358-1C5EEC9D-F73C-4333-8B39-48C840EC884BQ34503796-5125D9A9-52E9-4147-8DE1-D753D4E0341EQ34505575-7E5C53FF-3244-4D64-A273-1C7DAE0BA73FQ34710819-C76EB227-96AD-4451-84B8-64D7487A3AB9
P2860
Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Renal hemodynamic effect of so ...... with type 1 diabetes mellitus.
@en
type
label
Renal hemodynamic effect of so ...... with type 1 diabetes mellitus.
@en
prefLabel
Renal hemodynamic effect of so ...... with type 1 diabetes mellitus.
@en
P2093
P1433
P1476
Renal hemodynamic effect of so ...... with type 1 diabetes mellitus.
@en
P2093
Bruce A Perkins
David Z I Cherney
Hans J Woerle
Maria Maione
Maximilian von Eynatten
Nima Soleymanlou
Nora M Fagan
Uli C Broedl
P304
P356
10.1161/CIRCULATIONAHA.113.005081
P407
P577
2013-12-13T00:00:00Z